![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/spacer.gif) |
¿Preguntas sobre el cáncer?
![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/spacer.gif)
|
1-800-422-6237
(1-800-4-CANCER)
|
![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/spacer.gif)
|
Llame de lunes a viernes de 9:00 a.m. a 4:30 p.m., hora local en Estados Unidos y sus territorios. |
|
![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/spacer.gif)
| Anticuerpo monoclonal (tositumomab) que ha sido alterado químicamente por el agregado de yodo radiactivo. Se usa para tratar ciertos tipos de linfoma no Hodgkin. Es un tipo de anticuerpo monoclonal radioconjugado. La administración del tositumomab con yodo 131 y el tositumomab juntos se llama régimen de Bexxar. |
![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081101152423im_/http://www.nci.nih.gov/images/spacer.gif) |